Korea Exchange · Healthcare
Whan In Pharm stock from India: price, numbers and tax
Whan In Pharm (016580) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Whan In Pharm at a glance
- Price
- ₩10,180.00+₩0.00 (0.00%)
- Market cap
- ₩188.17B
- Day range
- ₩10,080.00 – ₩10,190.00
- P/E
- 9.00
- Dividend yield
- 2.95%
- Volume
- 14.79K
- 1 month
- -1.83%
- 6 months
- -0.49%
- YTD
- -10.07%
- 1 year
- -5.91%
- 5 years
- -42.65%
Whan In Pharm statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩255.2B | ₩259.6B | ₩230.4B | ₩198.9B | ₩177.8B |
| Gross profit | ₩106.7B | ₩93.8B | ₩98.1B | ₩98.8B | ₩93.5B |
| Operating income | ₩13.0B | ₩21.5B | ₩32.5B | ₩29.8B | ₩31.3B |
| Net income | ₩13.6B | ₩23.4B | ₩29.8B | ₩23.9B | ₩26.7B |
| Earnings per share | ₩857.00 | ₩1,532.37 | ₩1,950.23 | ₩1,566.86 | ₩1,746.22 |
| EBITDA | ₩24.1B | ₩33.4B | ₩40.5B | ₩34.9B | ₩38.2B |
| Total assets | ₩483.2B | ₩424.7B | ₩401.2B | ₩369.4B | ₩353.2B |
| Total debt | ₩679.0M | ₩413.7M | ₩632.0M | ₩249.9M | ₩1.7B |
| Cash and short-term investments | ₩63.6B | ₩52.6B | ₩78.5B | ₩87.3B | ₩146.0B |
| Shareholders' equity | ₩421.0B | ₩376.0B | ₩358.2B | ₩333.5B | ₩316.9B |
| Operating cash flow | ₩9.0B | ₩20.7B | ₩23.2B | ₩16.9B | ₩35.3B |
| Free cash flow | ₩6.2B | −₩8.7B | −₩8.3B | −₩50.9B | ₩30.6B |
| Capital expenditure | −₩2.9B | −₩29.4B | −₩31.5B | −₩67.8B | −₩4.8B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Samil Pharmaceutical | 000520.KS | ₩8,350.00 | ₩178.44B |
| JW Lifescience | 234080.KS | ₩10,940.00 | ₩169.40B |
| Ilsung Is | 003120.KS | ₩22,350.00 | ₩160.07B |
| Hana Pharm | 293480.KS | ₩8,470.00 | ₩150.11B |
| Dongwha Pharm | 000020.KS | ₩5,360.00 | ₩148.57B |
| Kyongbo Pharmaceutical | 214390.KS | ₩5,500.00 | ₩131.49B |
| SAMSUNG PHARM. | 001360.KS | ₩1,376.00 | ₩129.51B |
| Jeil Pharma | 002620.KS | ₩7,550.00 | ₩115.90B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Whan In Pharm from India
What Whan In Pharm does
Whan In Pharm Co.,Ltd. is a South Korean pharmaceutical enterprise specializing in the research, development, manufacturing, promotion, and distribution of therapeutic products. Their comprehensive portfolio encompasses treatments for mental health conditions (such as antidepressants and antipsychotics), neurological disorders (including nootropics, anti-dementia, and anti-epileptics), cardiovascular and gastrointestinal ailments, infectious diseases, allergies, pain and inflammation, metabolic imbalances, respiratory issues, and a variety of other central nervous system applications. Whan In Pharm operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Whan In Pharm shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.